Korean J Thorac Cardiovasc Surg.  2014 Dec;47(6):517-522. 10.5090/kjtcs.2014.47.6.517.

The Factors Affecting Recurrence of Symptoms after Infrainguinal Arterial Endovascular Angioplasty

Affiliations
  • 1Department of Thoracic and Cardiovascular Surgery, Pusan National University Hospital, Korea. chungsungwoon@hanmail.net
  • 2Department of Radiology, Pusan National University Hospital, Korea.

Abstract

BACKGROUND
This study reports the result of endovascular treatment for arterial occlusive disease limited to femoropopliteal lesions, focusing on the recurrence of symptoms instead of patency.
METHODS
This was a retrospective, single-center study. From April 2007 to November 2011, 48 limbs in 38 patients underwent endovascular stenting or balloon angioplasty to treat femoropopliteal arterial occlusive disease. The factors affecting the recurrence of symptoms were analyzed.
RESULTS
The mean age of the patients was 69.60+/-7.62 years. Among the baseline characteristics of the patients, initial hyperlipidemia was the most important factor affecting the recurrence of symptoms (relative risk=5.810, p=0.031). The presence of a dorsal arch was also a significant factor (relative risk=0.675, p=0.047).
CONCLUSION
The major factors that affect the recurrence of symptoms after endovascular treatment for femoropopliteal arterial occlusive lesions are hyperlipidemia and the presence of a dorsal arch. Therefore, the usage of lipid-lowering agents after endovascular treatment and taking the presence of a dorsal arch into consideration are important elements of managing the recurrence of symptoms.

Keyword

Atherosclerosis; Angioplasty; Lower extremity; Symptoms

MeSH Terms

Angioplasty*
Angioplasty, Balloon
Arterial Occlusive Diseases
Atherosclerosis
Extremities
Humans
Hyperlipidemias
Lower Extremity
Recurrence*
Retrospective Studies
Stents
Full Text Links
  • KJTCS
Actions
Cited
CITED
export Copy
Close
Share
  • Twitter
  • Facebook
Similar articles
Copyright © 2024 by Korean Association of Medical Journal Editors. All rights reserved.     E-mail: koreamed@kamje.or.kr